ARS Pharmaceuticals Enters Material Definitive Agreement

Ticker: SPRY · Form: 8-K · Filed: May 2, 2025 · CIK: 1671858

Ars Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyArs Pharmaceuticals, Inc. (SPRY)
Form Type8-K
Filed DateMay 2, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement

TL;DR

ARS Pharma signed a big deal, details TBD.

AI Summary

On May 2, 2025, ARS Pharmaceuticals, Inc. filed an 8-K report indicating the entry into a Material Definitive Agreement. The filing does not provide specific details about the agreement, parties involved, or financial terms within the provided text.

Why It Matters

This filing signals a significant business development for ARS Pharmaceuticals, potentially impacting its operations, partnerships, or financial standing.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

  • ARS Pharmaceuticals, Inc. (company) — Registrant
  • Silverback Therapeutics, Inc. (company) — Former company name
  • May 2, 2025 (date) — Date of Report

FAQ

What is the nature of the Material Definitive Agreement entered into by ARS Pharmaceuticals?

The provided filing states that ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement, but the specific details of this agreement are not disclosed in the text.

Who are the parties involved in this Material Definitive Agreement?

The filing does not specify the other parties involved in the Material Definitive Agreement.

What is the effective date of this Material Definitive Agreement?

The filing indicates that the date of the earliest event reported is May 2, 2025, which is also the date as of which the agreement is effective.

Does this filing provide any financial terms or obligations related to the agreement?

No, the provided text of the 8-K filing does not contain any information regarding financial terms or obligations associated with the Material Definitive Agreement.

What was ARS Pharmaceuticals' former company name?

ARS Pharmaceuticals, Inc.'s former company name was Silverback Therapeutics, Inc., with a date of name change on April 12, 2016.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding ARS Pharmaceuticals, Inc. (SPRY).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.